1.947

3.46% 0.067

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $1.947, with a volume of 787.49K. It is up +3.46% in the last 24 hours and up +0.78% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Previous Close:

$1.88

Open:

$1.88

24h Volume:

787.49K

Relative Volume:

0.50

Market Cap:

$188.69M

Revenue:

$20.76M

Net Income/Loss:

$-132.49M

P/E Ratio:

-0.7292

EPS:

-2.67

Net Cash Flow:

$-108.55M

1W Performance:

-9.11%

1M Performance:

+0.78%

6M Performance:

-8.25%

1Y Performance:

-42.11%

1-Day Range:

$1.88

$2.035

1-Week Range:

$1.83

$2.14

52-Week Range:

$1.085

$3.72

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1116)

Industry

Biotechnology (622)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

110

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	1.947	182.20M	20.76M	-132.49M	-108.55M	-2.67
VRTX Vertex Pharmaceuticals Inc	464.02	119.76B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	760.88	79.35B	14.34B	4.50B	3.88B	41.57
ARGX Argen X Se Adr	847.24	51.71B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	345.98	44.80B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	342.47	38.18B	4.98B	69.60M	525.67M	0.5198

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

07:00 AM

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

07:00 AM

Feb 02, 2026